Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients

Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S11-5. doi: 10.1053/ajkd.2001.27505.

Abstract

African-American renal transplant recipients have higher rates of acute allograft rejection and lower rates of allograft survival compared with Caucasian patients, and these differences have not been eliminated by a new generation of potent immunosuppressive drugs. In particular, African-Americans tend to exhibit higher rejection rates after withdrawal of corticosteroid therapy. Based on promising early results using the combination of sirolimus and low-dose tacrolimus in liver, kidney-pancreas, and islet-cell transplant recipients, our center is conducting a pilot study of this immunosuppression regimen in African-American patients. As of April 2001, there has been only 1 acute rejection episode (2.8%) in this cohort. Long-term follow-up of these patients will be necessary to assess the benefits and risks of this regimen.

Publication types

  • Comparative Study

MeSH terms

  • Adrenal Cortex Hormones / adverse effects
  • Adrenal Cortex Hormones / therapeutic use
  • African Continental Ancestry Group / genetics*
  • Drug Therapy, Combination
  • Graft Rejection / epidemiology
  • Graft Rejection / immunology*
  • Graft Survival / drug effects*
  • Graft Survival / genetics
  • Graft Survival / immunology
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation / immunology*
  • Pharmacogenetics
  • Sirolimus / adverse effects*
  • Sirolimus / therapeutic use*
  • Tacrolimus / adverse effects*
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Sirolimus
  • Tacrolimus